Poster-Disease-modifying Therapy
October 25, 2021
Psoriasis in Multiple Sclerosis Patients Treated with Disease Modifying Therapies
Background: Psoriasis may be more common in people living with multiple sclerosis (PwMS) than in the general population. Some pathways...
Poster-Disease-modifying Therapy
October 25, 2021
Effect of Age on the Change of Lymphocytes and Immunoglobulins during Treatment with Ocrelizumab or Rituximab for Multiple Sclerosis and Related Disorders
Background: Depletion of B lymphocytes is a known therapeutic strategy for multiple sclerosis (MS) and related disorders. Ocrelizumab (OCR)...